<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39142233</PMID><DateRevised><Year>2024</Year><Month>08</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2213-0772</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>13</Day></PubDate></JournalIssue><Title>Healthcare (Amsterdam, Netherlands)</Title><ISOAbbreviation>Healthc (Amst)</ISOAbbreviation></Journal><ArticleTitle>Outpatient remdesivir treatment program for hospitalized patients with coronavirus disease-2019: Patient perceptions, process and economic impact.</ArticleTitle><Pagination><StartPage>100750</StartPage><MedlinePgn>100750</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.hjdsi.2024.100750</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2213-0764(24)00017-4</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Remdesivir is FDA-approved for the treatment of hospitalized patients with severe COVID-19. Many patients improve clinically to allow for hospital dismissal before completing the 5-day course. In a prior work, patients who continued remdesivir in an outpatient setting experienced better 28-day clinical outcomes. Here, we assessed patients' perspectives and the economic impact of this outpatient practice.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Hospitalized patients who received remdesivir for COVID-19 at Mayo Clinic, Rochester, from 11/6/2020 to 11/5/2021 and were dismissed to continue remdesivir in the outpatient setting were surveyed. The cost of care was compared between those who remained hospitalized versus those who were dismissed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">93 (19.8&#xa0;%) among 470 eligible patients responded to the electronic survey. Responders were older than non-responders. The majority (70.5&#xa0;%) had symptoms resolved by the time of the survey. Ten (11.4&#xa0;%) patients had persistent symptoms attributed to long COVID-19. The majority were satisfied with the quality of care (82.3&#xa0;%) and overall experience (76.0&#xa0;%) in the infusion clinic. After adjusting for gender, comorbidity score, and WHO severity scale, the predicted costs for the groups were $16,544 (inpatient) and $9,097 (outpatient) per patient (difference of $7,447; p&#xa0;&lt;&#xa0;.01). An estimate of 1,077 hospital bed-days were made available to other patients as a result of this transition to outpatient.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">An outpatient remdesivir program that allowed for early dismissal was perceived favorably by patients. The program resulted in significant cost and resource savings, the latter in terms of the availability of hospital beds for other patients needing critical services.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chesdachai</LastName><ForeName>Supavit</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Public Health, Infectious Diseases, and Occupational Medicine, Mayo Clinic, Rochester, MN, USA. Electronic address: chesdachai.supavit@mayo.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rivera</LastName><ForeName>Christina G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosedahl</LastName><ForeName>Jordan K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Philpot</LastName><ForeName>Lindsey M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA; Department of Community Internal Medicine, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dholakia</LastName><ForeName>Ruchita</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borah</LastName><ForeName>Bijan J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Draper</LastName><ForeName>Evan W</ForeName><Initials>EW</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arndt</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Mayo Clinic Health System, Eau Claire, WI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ganesh</LastName><ForeName>Ravindra</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of General Internal Medicine, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larsen</LastName><ForeName>Jennifer J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Nursing, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Destro Borgen</LastName><ForeName>Molly J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Division of Public Health, Infectious Diseases, and Occupational Medicine, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Razonable</LastName><ForeName>Raymund R</ForeName><Initials>RR</Initials><AffiliationInfo><Affiliation>Division of Public Health, Infectious Diseases, and Occupational Medicine, Mayo Clinic, Rochester, MN, USA. Electronic address: razonable.raymund@mayo.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Healthc (Amst)</MedlineTA><NlmUniqueID>101622189</NlmUniqueID><ISSNLinking>2213-0764</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Cost analysis</Keyword><Keyword MajorTopicYN="N">Hospitalization</Keyword><Keyword MajorTopicYN="N">Remdesivir</Keyword><Keyword MajorTopicYN="N">SARS-2-CoV</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Raymund R. Razonable reports financial support was provided by Gilead. RRR received research funds from Regeneron and Roche on projects unrelated to this study, as member of the DSMB for Novartis, and is on the American Society of Transplantation Board of Directors. CGR has served as member of advisory board for Gilead Inc. BJB is a Boehringer Ingelheim and Exact Sciences Corporation consultant on unrelated projects. Others declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>15</Day><Hour>0</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>15</Day><Hour>0</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>14</Day><Hour>18</Hour><Minute>9</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39142233</ArticleId><ArticleId IdType="doi">10.1016/j.hjdsi.2024.100750</ArticleId><ArticleId IdType="pii">S2213-0764(24)00017-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>